3-[[4-(2-phenylethyl)-5-sulfanylidene-1H-1,2,4-triazol-3-yl]methyl]-1,3-benzothiazol-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 3-[[4-(2-phenylethyl)-5-sulfanylidene-1H-1,2,4-triazol-3-yl]methyl]-1,3-benzothiazol-2-one
• 化学式: C₁₈H₁₆N₄OS₂
• 分子量: 368.483
• InChiKey: RDIRENVLHXJZKT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  105
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-[[4-(2-phenylethyl)-5-sulfanylidene-1H-1,2,4-triazol-3-yl]methyl]-1,3-benzothiazol-2-one 、 氯乙酰胺 在 caesium carbonate 、 sodium iodide 作用下， 以 乙腈 为溶剂， 反应 12.0h， 以95%的产率得到2-((5-((2-oxobenzo[d]thiazol-3(2H)-yl)methyl)-4-phenethyl-4H-1,2,4-triazol-3-yl)thio)acetamide
  参考文献：
  名称：

  Rad51 / BRCA2干扰物可抑制胰腺癌细胞中的同源重组并与奥拉帕尼协同作用

  摘要：

  Olaparib是一种PARP抑制剂（PARPi）。对于携带BRCA1或BRCA2突变的患者，奥拉帕尼被批准用于治疗卵巢癌，并在临床试验中被批准用于治疗乳腺癌和胰腺癌。在BRCA2缺陷患者中，PARPi抑制DNA单链断裂修复，而BRCA2突变阻碍双链断裂修复。最近，我们发现了一系列三唑衍生物，它们通过破坏Rad51-BRCA2的相互作用从而模拟双链断裂修复来模拟BRCA2突变。在这里，我们已经通过计算设计，合成和测试了40多种新型衍生物。此外，我们设计并进行了新颖的生物学分析，以表征它们如何破坏Rad51-BRCA2相互作用并抑制双链断裂修复。这些化合物与olaparib协同作用，靶向具有功能性BRCA2的胰腺癌细胞。这支持了有机小分子可以模仿基因突变以改善精密医学用抗癌药物的观点的观点。此外，可以在其他遗传途径中利用这种范例来发现创新的抗癌靶标和候选药物。

  DOI：

  10.1016/j.ejmech.2019.01.008
• 作为产物：
  描述：

  在 sodium carbonate 作用下， 以 乙醇 为溶剂， 反应 4.0h， 以83%的产率得到3-[[4-(2-phenylethyl)-5-sulfanylidene-1H-1,2,4-triazol-3-yl]methyl]-1,3-benzothiazol-2-one
  参考文献：
  名称：

  Synthesis and antinociceptive activity of [(2-oxobenzothiazolin-3-yl)methyl]-4-alkyl/aryl-1,2,4-triazoline-5-thiones

  摘要：

  The synthesis and pharmacological evaluation of new [(2-oxobenzothiazolin-3-yl)-methyl]-4-alkyl/aryl-1,2,4-triazoline-5-thiones are reported. All compounds were screened for analgesic and antiinflammatory activities by using the AcOH induced-stretching test, the hot plate test, the tail clip test, and the tail flick test. All of the title compounds showed more potent activity than the standard compound aspirin in the AcOH induced-stretching test. In the hot plate test [(2-oxobenzothiazolin-3-yl)methyl]-4-phenethyl-1,2,4-triazoline-5-thione 5j were revealed to be two-fold more potent in antinociceptive activity than novalgine. However, in the tail flick and tail clip test none of the compounds showed an antinociceptive activity as high as that of novalgine. On the basis of available data the structure-activity relationship in the [(2-oxobenzothiazolin-3-yl)methyl]-4-alkyl/aryl-1,2,4-triazoline-5-thiones was also discussed.

  DOI：

  10.1002/1521-4184(200109)334:8/9<279::aid-ardp279>3.0.co;2-w

文献信息

• Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells
  作者：Marinella Roberti、Fabrizio Schipani、Greta Bagnolini、Domenico Milano、Elisa Giacomini、Federico Falchi、Andrea Balboni、Marcella Manerba、Fulvia Farabegoli、Francesca De Franco、Janet Robertson、Saverio Minucci、Isabella Pallavicini、Giuseppina Di Stefano、Stefania Girotto、Roberto Pellicciari、Andrea Cavalli

  DOI：10.1016/j.ejmech.2019.01.008

  日期：2019.3

  double-strand break repair. Here, we have computationally designed, synthesized, and tested over 40 novel derivatives. Additionally, we designed and conducted novel biological assays to characterize how they disrupt the Rad51-BRCA2 interaction and inhibit double-strand break repair. These compounds synergized with olaparib to target pancreatic cancer cells with functional BRCA2. This supports the idea that

  Olaparib是一种PARP抑制剂（PARPi）。对于携带BRCA1或BRCA2突变的患者，奥拉帕尼被批准用于治疗卵巢癌，并在临床试验中被批准用于治疗乳腺癌和胰腺癌。在BRCA2缺陷患者中，PARPi抑制DNA单链断裂修复，而BRCA2突变阻碍双链断裂修复。最近，我们发现了一系列三唑衍生物，它们通过破坏Rad51-BRCA2的相互作用从而模拟双链断裂修复来模拟BRCA2突变。在这里，我们已经通过计算设计，合成和测试了40多种新型衍生物。此外，我们设计并进行了新颖的生物学分析，以表征它们如何破坏Rad51-BRCA2相互作用并抑制双链断裂修复。这些化合物与olaparib协同作用，靶向具有功能性BRCA2的胰腺癌细胞。这支持了有机小分子可以模仿基因突变以改善精密医学用抗癌药物的观点的观点。此外，可以在其他遗传途径中利用这种范例来发现创新的抗癌靶标和候选药物。
• Synthesis and antinociceptive activity of [(2-oxobenzothiazolin-3-yl)methyl]-4-alkyl/aryl-1,2,4-triazoline-5-thiones
  作者：M. Gökce、B. Cakir、K. Erol、M. F. Sahin

  DOI：10.1002/1521-4184(200109)334:8/9<279::aid-ardp279>3.0.co;2-w

  日期：2001.9

  The synthesis and pharmacological evaluation of new [(2-oxobenzothiazolin-3-yl)-methyl]-4-alkyl/aryl-1,2,4-triazoline-5-thiones are reported. All compounds were screened for analgesic and antiinflammatory activities by using the AcOH induced-stretching test, the hot plate test, the tail clip test, and the tail flick test. All of the title compounds showed more potent activity than the standard compound aspirin in the AcOH induced-stretching test. In the hot plate test [(2-oxobenzothiazolin-3-yl)methyl]-4-phenethyl-1,2,4-triazoline-5-thione 5j were revealed to be two-fold more potent in antinociceptive activity than novalgine. However, in the tail flick and tail clip test none of the compounds showed an antinociceptive activity as high as that of novalgine. On the basis of available data the structure-activity relationship in the [(2-oxobenzothiazolin-3-yl)methyl]-4-alkyl/aryl-1,2,4-triazoline-5-thiones was also discussed.